Hidden Steroids and NSAIDs in Joint-Pain Products

Some joint-pain products sold as herbal supplements take the pain of arthritis away within days. Herbs do not do that. Prescription drugs do. Twice in the last fifteen years the U.S. Food and Drug Administration (FDA) has tested popular “natural” arthritis remedies and found the same three prescription drugs hidden inside: dexamethasone (a powerful steroid), diclofenac (a non-steroidal anti-inflammatory drug, or NSAID) and methocarbamol (a muscle relaxant). None was on the label. This page explains how the pattern works, what the FDA record actually says about Reumofan Plus and the Artri King family, what each hidden drug does to a body over months, and — the single most important point on the page — why a person who has been taking one of these products for weeks must not stop suddenly without a doctor's help.

Table of Contents

  1. The pattern: an herbal remedy that works too well
  2. The record: Reumofan Plus (2012)
  3. The record: Artri King and its relatives (2022–2026)
  4. What hidden dexamethasone does over months
  5. The adrenal-suppression trap
  6. What hidden diclofenac does: stomach, kidneys, heart
  7. Methocarbamol: sedation and falls
  8. Warfarin and other interactions
  9. Why older adults are the target market
  10. How to recognise the pattern
  11. What to do if you have been taking one
  12. How to check a product against the FDA list
  13. The honest bottom line
  14. Research Papers
  15. Connections
  16. Featured Videos

1. The pattern: an herbal remedy that works too well

Genuine herbal products for joint pain — turmeric, boswellia, ginger, nettle (ortiga in Spanish), garlic (ajo) — have modest effects that build over weeks, if they build at all. A product that stops arthritis pain in two or three days, lets a stiff person get out of a chair easily and brings back an appetite is behaving like a prescription. The simplest explanation is usually the right one: it contains a prescription.

The combination that keeps turning up is not random. A steroid such as dexamethasone shuts down inflammation everywhere in the body and produces a sense of well-being; an NSAID such as diclofenac kills pain; a muscle relaxant such as methocarbamol eases the guarding and spasm around a sore joint. Together they make almost any arthritis feel better within days, which is exactly why they sell. The harm comes from taking three prescription drugs blind: in unknown and varying doses, with no monitoring, without the label warnings, and without a pharmacist who could have caught the interactions with the medicines already in the cabinet.

The rest of this page teaches the pattern rather than a list of brand names, because the names change. Two are named below because the FDA record on them is public, detailed and worth reading in full.

2. The record: Reumofan Plus (2012)

On June 1, 2012 the FDA warned consumers that Reumofan Plus, marketed as a “natural” dietary supplement, labelled in Spanish, made in Mexico by Riger Naturals and sold in retail outlets, at flea markets and on the internet, contained prescription drugs not listed on the label. The FDA's own laboratory found diclofenac sodium and methocarbamol; the Mexican Ministry of Health had found that at least one lot also contained the corticosteroid dexamethasone, and had ordered the product recalled. The product was being promoted for arthritis, muscle pain, osteoporosis, bone cancer and other conditions. By then the FDA had already received adverse-event reports that it listed as “liver injury, sudden worsening of glucose (sugar) control, weight gain, swelling, leg cramps, and adrenal suppression,” and at least one treating clinician had confirmed adrenal suppression in a patient.

On August 21, 2012 the FDA issued a second alert covering Reumofan Plus and Reumofan Plus Premium. Its ongoing analyses of Reumofan Plus had now found all three drugs — dexamethasone, diclofenac sodium and methocarbamol — while Reumofan Plus Premium contained diclofenac sodium and methocarbamol. The agency reported that it had “received dozens of additional adverse event reports, including death and stroke,” since the first warning, with other reports of “liver injury, severe bleeding, sudden worsening of glucose (sugar) control, weight gain, swelling, leg cramps and withdrawal syndrome, and adrenal suppression.” It urged clinicians to ask patients about the product and to consider a corticosteroid taper for anyone who had used it. U.S. distributors recalled lots in August 2012 and February 2013; the 2013 recall notice for lot 99515 listed methocarbamol, dexamethasone and diclofenac and noted one illness reported in connection with it. The primary documents are in the Regulatory Records list below.

3. The record: Artri King and its relatives (2022–2026)

Ten years later the same drugs reappeared in a family of products carrying the names Artri and Ortiga, sold on major online marketplaces and in some stores. The FDA record, product by product:

On April 20, 2022 the FDA told consumers not to buy or use any product with “Artri” or “Ortiga” in its name and stated, in its own words: “FDA has received adverse event reports, including of liver toxicity and death, associated with the use of Artri King products, since the agency issued its first warning about an Artri Ajo King product on January 5, 2022.” The agency did not publish a count in that alert. In a July 3, 2023 update it said that since April 2022 “more than 30 additional consumers have experienced a serious health effect” after using these products, listing “sudden weight gain, serious gastrointestinal damage including bleeding and ulceration, increased blood glucose (sugar) levels, adrenal dysfunction, liver toxicity, and other serious conditions,” and adding that “some of these problems can be life threatening or fatal.” Walmart (May 2022) and Latin Foods Market (June 2022) recalled lots; in October 2022 the FDA sent warning letters to Amazon, Walmart and Latin Foods Market for distributing the products, and it later issued an import alert.

Two points in the FDA's alert matter for every product of this type. First, the analyses “reflect only the undeclared ingredients discovered in one product from a specific lot, but ingredients may vary from product to product or from lot to lot” — a bottle can contain more, less or different drugs than the one the FDA tested. Second, the agency's instruction to users was not simply to stop, but to “immediately talk to their health care professional” to discontinue safely, “because suddenly stopping these drugs may be dangerous.” Section 5 explains why.

The medical literature has caught up with the record. A 2025 systematic review in the Southern Medical Journal gathered 16 published patients from 10 reports who had taken Artri King for an average of roughly 13 to 17 months; three-quarters had been diagnosed with Cushing syndrome, and the serious effects reported were Cushing syndrome, adrenal insufficiency and worsening high blood sugar, with fragility fractures the most common presenting problem at the authors' own hospital. A 2023 emergency-medicine case report describes a patient who had taken Artri Ajo King for 18 months, stopped abruptly, and arrived in the emergency department with abdominal pain, vomiting and weakness; a stimulation test confirmed secondary adrenal insufficiency, and hydrocortisone resolved it.

4. What hidden dexamethasone does over months

Dexamethasone is one of the most potent and longest-acting of the synthetic glucocorticoids — the family of drugs that copy cortisol, the body's main stress hormone. Doctors prescribe it deliberately for short courses or for serious disease, with the dose known and the risks weighed. Taken every day for months, in an unknown dose, it produces a recognisable picture. The FDA's alert lists the harms as “infections, increased blood glucose (sugar) levels, changes in blood pressure, damage to bones, psychiatric problems, and adrenal dysfunction.” In plain terms:

Every one of these effects is dose- and time-dependent, and with a hidden steroid the dose is unknown and the time is however long the bottles kept coming.

5. The adrenal-suppression trap: why stopping suddenly is dangerous

This is the most important section on the page. The adrenal glands make cortisol on instruction from the pituitary gland, which takes its cue from the hypothalamus in the brain — the hypothalamic-pituitary-adrenal (HPA) axis. Cortisol is not optional: it holds up blood pressure, keeps blood sugar from collapsing and lets the body survive illness, injury and surgery. When a steroid drug is present every day, the brain reads “plenty of cortisol” and stops sending the signal. Over weeks the adrenal glands, unused, shrink. The person feels fine, because the drug is doing cortisol's job.

Then the bottle runs out, or a worried family member throws it away, or a doctor says “stop that at once.” The drug leaves the body, the adrenal glands cannot restart on demand, and the person is suddenly living with no cortisol at all. That is adrenal insufficiency, and its severe form, adrenal crisis, is a medical emergency: profound weakness, nausea and vomiting, abdominal pain, dizziness and fainting from low blood pressure, low blood sugar, confusion and collapse. It can be fatal, and it is most likely to strike during an infection or other stress, exactly when cortisol is needed most. The FDA's alerts describe the withdrawal picture as “fatigue, nausea, low blood pressure, low blood glucose levels, fever, dizziness, muscle and joint pain, and shortness of breath.” The 18-month Artri Ajo King case in Section 3 is this trap in action.

How common is it? A 2015 meta-analysis of 74 studies (3,753 people tested) found adrenal insufficiency after corticosteroid use ranging from about 2% with low doses to about 22% with high doses, and from about 1% after courses shorter than four weeks to about 27% after more than a year; the authors concluded that there is “no administration form, dosing, treatment duration, or underlying disease for which adrenal insufficiency can be excluded with certainty.” A 2016 systematic review found a median of 37% of tested patients affected, documented suppression even below 5 mg of prednisolone a day and after fewer than four weeks, and found that 15% of patients still had adrenal insufficiency when retested three years after stopping. A product taken daily for a year sits at the high-risk end of every one of those scales.

Why a doctor must manage the stop. The 2024 joint guideline of the European Society of Endocrinology and the Endocrine Society sets out how: taper reasonably quickly while the dose is still above what the body makes itself, then slowly once it is near physiological levels, while the adrenal glands recover — a recovery that “varies greatly amongst individuals.” With a hidden steroid there is an extra problem: nobody knows the starting dose. In practice a clinician will usually switch the person to a known steroid such as hydrocortisone or prednisone, taper that on a schedule, check a morning cortisol along the way, and teach “sick-day rules” — extra steroid during illness, and when to go to the emergency department. A person who has been taking one of these products for more than two or three weeks should keep taking their usual amount until they have been seen; that is not a concession to the product, it is the safe bridge off it.

6. What hidden diclofenac does: stomach, kidneys, heart

Diclofenac is an effective prescription NSAID, and one of the riskier ones. The Coxib and traditional NSAID Trialists' Collaboration pooled 280 placebo-controlled trials and 474 head-to-head trials in The Lancet in 2013 and found that diclofenac raised major vascular events (heart attack, stroke or vascular death) by about 40%, chiefly through a 70% rise in major coronary events — a risk comparable to the COX-2 inhibitors. All NSAIDs roughly doubled the risk of heart failure. Diclofenac also nearly doubled serious upper-gastrointestinal complications (bleeding, perforation, obstruction). A 2018 Danish study of 1.37 million people starting diclofenac put the short-term picture in sharper focus: within 30 days, major cardiovascular events were 50% more frequent than in matched non-users, the risk was present even at low doses, and upper-gastrointestinal bleeding was roughly four and a half times more frequent.

The kidneys are the third target. NSAIDs constrict the small vessels that keep the kidney filtering, and a 2017 meta-analysis found current NSAID use raised the odds of acute kidney injury by 73% in the general population and by about two and a half times in older people; anyone with existing kidney disease starts from a higher baseline. Diclofenac is also among the NSAIDs most often linked to liver injury; the FDA's Artri alert lists “liver toxicity including liver failure that can cause the need for a liver transplant or death” among its possible effects.

Now put the steroid and the NSAID in the same tablet. A classic 1991 study of Tennessee Medicaid patients found that oral corticosteroids on their own barely raised the risk of peptic ulcer (relative risk 1.1), but people taking a corticosteroid and an NSAID had about 15 times the ulcer risk of people taking neither. These products are that combination, taken daily, by people who have no idea they are taking it.

7. Methocarbamol: sedation and falls

Methocarbamol is the least dramatic of the three and still matters. The FDA's notices describe it plainly: it “can cause sedation, dizziness, and low blood pressure” and can impair the ability to drive or operate machinery. The American Geriatrics Society's 2023 Beers Criteria — the standard list of medicines best avoided in adults 65 and older — puts skeletal muscle relaxants, methocarbamol among them, in the “avoid” column because they are “poorly tolerated by older adults due to anticholinergic adverse effects, sedation, and increased risk of fractures,” while their effectiveness at doses older people can tolerate is questionable.

In a joint-pain product the danger compounds: a drowsy, light-headed person with steroid-thinned bones is a fall waiting to happen, and in this population a fall is a fracture. The Artri King literature's most common presentation — fragility fractures — is what that arithmetic looks like on a ward.

8. Warfarin and other interactions

An undeclared drug defeats the safety net that ordinarily catches dangerous combinations. The pharmacist's interaction check cannot fire on an ingredient that is not on the label, and neither the patient nor the doctor knows to look.

Warfarin and other blood thinners. An NSAID damages the stomach lining and blunts platelets; an anticoagulant stops the clot that would normally seal a small bleed. Among Ontario residents over 66 taking warfarin, those admitted to hospital with upper-gastrointestinal bleeding were about twice as likely (odds ratio 1.9) to have also been taking a conventional NSAID. The FDA's Reumofan alerts list “severe bleeding” and its Artri alert lists “bleeding and ulceration” among the reported harms. The same logic applies to apixaban, rivaroxaban, dabigatran, clopidogrel and daily aspirin.

Other NSAIDs. Someone whose joints still hurt may add over-the-counter ibuprofen or naproxen on top of the hidden diclofenac — the “multiple NSAID-containing products” situation the FDA specifically warns about — doubling the stomach, kidney and heart risks.

Blood-pressure, heart and kidney medicines. NSAIDs blunt the effect of blood-pressure drugs and, combined with a diuretic and an ACE inhibitor or ARB, sharply raise the risk of acute kidney injury; they also worsen fluid retention in heart failure, as does the steroid.

Diabetes medicines. The hidden steroid pushes glucose up, so doses that were correct become inadequate; if the product is later stopped, those raised doses can then cause hypoglycaemia.

Sedatives, alcohol and opioids. Methocarbamol adds to their drowsiness and to the risk of falls and of slowed breathing.

9. Why older adults are the target market — and the most vulnerable

Arthritis is a disease of age, so these products are sold where older people shop: Spanish-language markets, flea markets, small grocers and online marketplaces, with labels that promise relief from arthritis, muscle pain and osteoporosis in one bottle. Reumofan Plus was labelled in Spanish; the Artri and Ortiga products were sold through Amazon, Walmart.com and Latin Foods Market. A person in daily pain who has been told that nothing more can be done is the ideal customer for something that works in three days.

Older adults are also the people least able to absorb the hidden drugs. Kidney function declines with age, so the NSAID's kidney risk is higher (about two and a half times the odds of acute kidney injury in older people in the 2017 meta-analysis). They are the most likely to be on warfarin or another blood thinner, on blood-pressure medicines, and on diabetes treatment. Their bones are already thinner, so the steroid's bone loss reaches the fracture threshold sooner. They fall more easily, which is why the Beers Criteria single out muscle relaxants. And they are most likely to be taking several other medicines with which the hidden ingredients interact. Every risk on this page is larger in a 75-year-old than in a 40-year-old, and the market is built around the 75-year-old.

10. How to recognise the pattern

Suspect a hidden drug when a “natural” joint product produces any of the following:

11. What to do if you have been taking one

  1. Do not stop abruptly if you have taken it daily for more than about two weeks. Keep taking your usual amount until you have spoken to a clinician, for the reasons in Section 5. The FDA's own advice is to talk to a health care professional to discontinue safely because “suddenly stopping these drugs may be dangerous.”
  2. Bring the bottle — the actual product, with its label and lot number — to a doctor or pharmacist. Tell them how long you have taken it and how many a day. Ask whether it appears in the FDA's Health Fraud Product Database (Section 12).
  3. Ask for an early-morning cortisol (drawn around 8 a.m.), and depending on the result a stimulation test. Ask also for glucose or HbA1c, kidney function, a blood count for hidden bleeding, blood pressure, and, if the product has been used for months, a conversation about bone density.
  4. Expect a taper, not a stop, if the cortisol is low or you have been taking the product for months. Ask for written sick-day rules and whether you should carry a steroid card or alert while the adrenal glands recover.
  5. Review every other medicine with the pharmacist — especially warfarin or another blood thinner, other painkillers, blood-pressure and diabetes medicines — because doses may have been adjusted, unknowingly, around the hidden drugs.
  6. If you have already stopped and within days feel severely weak, are vomiting, feel faint on standing, or become confused, treat it as an emergency: call 911 or go to the emergency department and say you may have adrenal insufficiency after stopping a product that contained a hidden steroid. For advice at any hour, Poison Control is 1-800-222-1222.
  7. Report it. FDA MedWatch takes reports from patients as well as clinicians, online or at 1-800-FDA-1088; each report is how a product reaches the warning list. Do not swap to a sister product with a similar name — the record shows they share the same hidden ingredients.

12. How to check a product against the FDA list

The FDA keeps two public tools. The Health Fraud Product Database lists every product the agency has found to contain hidden drug ingredients, with the date, the ingredients found and a link to the notice; search it by product name before buying, and try partial names (“Artri,” “Ortiga,” “Reumofan”) because imitators reuse fragments. The Pain and Arthritis Products Containing Hidden Ingredients page lists the joint-pain products specifically, newest first. Both links are in the Regulatory Records below.

Two cautions. Absence from the list is not clearance: the FDA states in every notice that it “is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients.” And presence on the list is not the end of the product: the FDA had to re-warn about Artri products in 2023, 2025 and 2026, and a 2014 study in JAMA found that two-thirds of supplements re-purchased after an FDA recall still contained the banned drug. The list is a tool; the pattern in Section 10 is the protection.

13. The honest bottom line

These products work. That is the whole problem. They work because they are a steroid, an NSAID and a muscle relaxant, and the relief they give is real. What is not real is the label, and with it everything that makes those drugs usable: a known dose, a doctor's judgement about whether your stomach, kidneys, heart and bones can take them, a pharmacist's check against your other medicines, and a plan for coming off the steroid without a crisis.

If you want the effect, you can have it honestly. A physician can prescribe diclofenac with a stomach-protecting drug and a kidney check, or a short, deliberate steroid course, or refer you for the treatments that actually change the course of arthritis. What no one should do is take dexamethasone for a year without knowing it. And if you already have, the way out is not the bin — it is a bottle in one hand, a doctor in the other, and a morning cortisol on the way.

Back to Table of Contents

Research Papers

  1. Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9 — diclofenac raised major vascular events by about 40% and major coronary events by 70%; all NSAIDs roughly doubled heart failure; diclofenac nearly doubled upper-GI complications.
  2. Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018;362:k3426. doi:10.1136/bmj.k3426 — 1.37 million diclofenac starters: 50% more major cardiovascular events within 30 days than non-users, present even at low doses; upper-GI bleeding about 4.5-fold.
  3. Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256. doi:10.1186/s12882-017-0673-8 — current NSAID use: odds of acute kidney injury 1.73 in the general population and 2.51 in older people.
  4. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735-740. doi:10.7326/0003-4819-114-9-735 — corticosteroids alone barely raised ulcer risk (RR 1.1); corticosteroid plus NSAID carried about 15 times the risk of neither drug.
  5. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165(2):189-192. doi:10.1001/archinte.165.2.189 — among 98,821 warfarin users over 66, those hospitalised for upper-GI bleeding were about twice as likely to be taking a nonselective NSAID (OR 1.9).
  6. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171-2180. doi:10.1210/jc.2015-1218 — 74 studies, 3,753 people: adrenal insufficiency from 2.4% (low dose) to 21.5% (high dose) and from 1.4% (under 28 days) to 27.4% (over a year); no regimen excludes it with certainty.
  7. Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. Semin Arthritis Rheum. 2016;46(1):133-141. doi:10.1016/j.semarthrit.2016.03.001 — median 37% of tested patients affected; suppression documented below 5 mg prednisolone a day and under four weeks; 15% still insufficient three years after stopping.
  8. Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. Eur J Endocrinol. 2024;190(5):G25-G51. doi:10.1093/ejendo/lvae029 — how to taper: faster above physiological doses, slower near them; recovery of adrenal function varies greatly between individuals.
  9. 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 — skeletal muscle relaxants including methocarbamol: avoid in adults 65 and older (sedation, anticholinergic effects, fractures).
  10. Chun M, Sutton J, Chung J, et al. The adverse effects of Artri King: a systematic review and case series. South Med J. 2025;118(7):376-381. doi:10.14423/SMJ.0000000000001851 — 16 published patients from 10 reports; 75% diagnosed with Cushing syndrome; adrenal insufficiency and worsening hyperglycaemia; fragility fractures the commonest presentation at the authors' hospital.
  11. Boncompagni AC, Ruiz E, Rider AC. A case of iatrogenic Cushing syndrome and subsequent adrenal insufficiency from a hidden ingredient in the supplement Artri Ajo King. JACEP Open. 2023;4(4):e13007. doi:10.1002/emp2.13007 — 18 months of use, abrupt cessation, emergency presentation with vomiting and weakness; secondary adrenal insufficiency confirmed by stimulation test and treated with hydrocortisone.
  12. Berg EA, Dao L, Yu R, Hurtado C. Artri King-induced hypothalamic-pituitary-adrenal axis disruption: a report of 3 cases. JCEM Case Rep. 2023;2(1):luad154. doi:10.1210/jcemcr/luad154 — three Artri King users: low sodium, weight gain, proximal weakness, a neck fat pad and striae with a raised serum dexamethasone level; cushingoid features with a low morning cortisol; poorly controlled diabetes.
  13. Cohen PA, Maller G, DeSouza R, Neal-Kababick J. Presence of banned drugs in dietary supplements following FDA recalls. JAMA. 2014;312(16):1691-1693. doi:10.1001/jama.2014.10308 — about two-thirds of supplements bought again after an FDA recall still contained a banned drug.

Regulatory Records

  1. FDA news release, June 1, 2012: FDA issues alert on Reumofan Plus. FDA Archive copy (the FDA's Health Fraud Product Database links this archived page as the primary record).
  2. FDA news release, August 21, 2012: FDA issues new safety alert on Reumofan Plus and Reumofan Plus Premium. FDA Archive copy.
  3. FDA MedWatch safety alert, posted June 1, 2012 and updated through February 19, 2013: Reumofan Plus: Recall – Undeclared Drug Ingredient. FDA Archive copy.
  4. FDA public notification, January 5, 2022, updated April 20, 2022 and March 3, 2026: Artri Ajo Rey and Artri Ajo King may be harmful due to hidden drug ingredients. fda.gov.
  5. FDA public notification, April 20, 2022: Artri King contains hidden drug ingredients. fda.gov.
  6. FDA public notification, April 20, 2022: Ortiga Mas Ajo Rey Extra Forte contains hidden drug ingredients. fda.gov.
  7. FDA CDER alert, April 20, 2022, updated October 28, 2022 and July 3, 2023: FDA warns consumers not to purchase or use Artri and Ortiga products, which may contain hidden drug ingredients. archived copy — the source of the adverse-event statements quoted above; fda.gov no longer serves the original address, though the notifications above still link to it.
  8. Recall notices posted by FDA: Walmart Inc., May 28, 2022 (Artri Ajo King, diclofenac) and Latin Foods Market, June 2022 (Artri King Reforzado con Ortiga y Omega 3, diclofenac and dexamethasone).
  9. FDA public notification, April 25, 2025: Artrifan King may be harmful due to hidden drug ingredients. fda.gov.
  10. FDA Health Fraud Product Database — the searchable list of products found to contain hidden drug ingredients. fda.gov.
  11. FDA Pain and Arthritis Products Containing Hidden Ingredients — the joint-pain notices, newest first. fda.gov.
  12. FDA MedWatch — report a side effect from any product. fda.gov, or 1-800-FDA-1088.

Back to Table of Contents

Connections

Back to Table of Contents